Last reviewed 2026-04-23 · How we verify

AMG 714

AMG 714 is an interleukin-6 (IL-6) receptor antagonist that blocks IL-6 signaling to reduce inflammation.

AMG 714 is an interleukin-6 (IL-6) receptor antagonist that blocks IL-6 signaling to reduce inflammation. Used for Rheumatoid arthritis, Systemic lupus erythematosus.

At a glance

Mechanism of action

AMG 714 binds to and inhibits the IL-6 receptor, preventing IL-6-mediated inflammatory signaling. This mechanism is intended to reduce systemic inflammation in autoimmune and inflammatory conditions. By blocking IL-6, the drug aims to suppress the inflammatory cascade that drives disease pathology in conditions like rheumatoid arthritis and other IL-6-driven inflammatory disorders.

Approved indications

• Rheumatoid arthritis
• Systemic lupus erythematosus

Common side effects

• Infection
• Elevated liver enzymes
• Neutropenia

Key clinical trials

• Evaluation of AMG 714 for Vitiligo (PHASE2)
• AMG 714 Expanded Access Program
• Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease (PHASE2)
• A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease (PHASE2)
• AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects (PHASE2)
• Phase 2 AMG 714 in Rheumatoid Arthritis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AMG 714 CI brief — competitive landscape report
• AMG 714 updates RSS · CI watch RSS
• Amgen portfolio CI